CAMBRIDGE, Mass. – C4 Therapeutics (C4T) today announced the appointment of Scott Armstrong, M.D, Ph.D., and Ross Levine, MD, to the Company’s Scientific Advisory Board (SAB).
“C4T has established a scientific advisory board that brings together leading scientists and physicians representing a range of disciplines,” said Andrew (Andy) Phillips, Ph.D., President and Chief Scientific Officer of C4 Therapeutics
“We are delighted to have Scott and Ross, both expert physician-scientists in the hematology-oncology field, join our team to advise us as we advance our technology and deliver on our key research objectives and operational goals of the Company.”
“It is an honor to join C4T’s Scientific Advisory Board at such an exciting time in the company’s growth. I am thrilled to have the opportunity to contribute to the ongoing development of the Company’s targeted protein degradation platform as it presents a novel approach to the treatment of human disease,” said Scott Armstrong, MD, Ph.D.
“I am eager to contribute to C4T’s transformative science that has the potential to offer several advantages for the treatment of cancer and other diseases,” said Ross Levine, MD. “C4T’s rapid progress in the field of targeted protein degradation presents a very promising opportunity to develop effective new treatments in a multitude of disease areas.”
Scott Armstrong, MD, Ph.D., is the Chairman of the Department of Pediatric Oncology and the Director of the Center for Pediatric Cancer Therapeutics at the Dana-Farber Cancer Institute (DFCI). He is also the David G. Nathan Professor of Pediatrics at Harvard Medical School and Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital. His laboratory program studies the role of histone modifications and chromosome structure as a critical initial step in leukemia development. Dr. Armstrong received his MD and Ph.D. from the University of Texas Southwestern Medical School. He performed his residency and fellowship in pediatric hematology/oncology at Children’s Hospital Boston, DFCI, and Harvard Medical School.
Ross Levine, MD, is an attending physician and the Laurence Joseph Dineen Chair in Leukemia Research at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program and Leukemia Service. Additionally, he is a Professor of Medicine at Weill Cornell Medical College and is the Director of the MSK Center for Hematologic Malignancies. His laboratory program is focused on the molecular basis of myeloid malignancies, with a specific focus on signaling and epigenetics and mechanism based therapeutics. Dr. Levine trained in internal medicine at Massachusetts General Hospital and in hematology-oncology at the Dana Farber Cancer Institute. Dr. Levine received his M.D. from The Johns Hopkins University School of Medicine and his A.B. from Harvard College.
About C4 Therapeutics
C4 Therapeutics is pioneering a new class of drugs. C4’s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
MacDougall Biomedical Communications
Kari Watson or Kara Mazey